Insider Transactions in Q4 2024 at Natera, Inc. (NTRA)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 31
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,866
-2.64%
|
$235,116
$126.45 P/Share
|
|
Oct 29
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
754
-1.06%
|
$89,726
$119.93 P/Share
|
|
Oct 28
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,238
-1.7%
|
$146,084
$118.21 P/Share
|
|
Oct 28
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
3,960
-2.04%
|
$467,280
$118.21 P/Share
|
|
Oct 28
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
929
-0.81%
|
$109,622
$118.21 P/Share
|
|
Oct 28
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,196
-1.07%
|
$141,128
$118.21 P/Share
|
|
Oct 28
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,057
-0.51%
|
$124,726
$118.21 P/Share
|
|
Oct 25
2024
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.78%
|
-
|
|
Oct 25
2024
|
Roelof Botha |
BUY
Grant, award, or other acquisition
|
Direct |
203
+5.11%
|
-
|
|
Oct 25
2024
|
James Healy |
BUY
Grant, award, or other acquisition
|
Direct |
153
+0.33%
|
-
|
|
Oct 25
2024
|
Herm Rosenman |
BUY
Grant, award, or other acquisition
|
Direct |
178
+0.27%
|
-
|
|
Oct 25
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
691
-0.94%
|
$81,538
$118.81 P/Share
|
|
Oct 24
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
914
-1.23%
|
$108,766
$119.19 P/Share
|
|
Oct 23
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
496
-0.66%
|
$59,024
$119.09 P/Share
|
|
Oct 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.64%
|
-
|
|
Oct 22
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
199
-0.17%
|
$23,880
$120.07 P/Share
|
|
Oct 22
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
256
-0.23%
|
$30,720
$120.07 P/Share
|
|
Oct 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
454
-0.61%
|
$54,480
$120.07 P/Share
|
|
Oct 22
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
893
-0.46%
|
$107,160
$120.07 P/Share
|
|
Oct 22
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
349
-0.17%
|
$41,880
$120.07 P/Share
|
|
Oct 21
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
342
-0.3%
|
$41,040
$120.76 P/Share
|
|
Oct 21
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
294
-0.26%
|
$35,280
$120.76 P/Share
|
|
Oct 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
608
-0.81%
|
$72,960
$120.76 P/Share
|
|
Oct 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+1.51%
|
-
|
|
Oct 21
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,709
-0.87%
|
$205,080
$120.76 P/Share
|
|
Oct 21
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,775
+0.9%
|
-
|
|
Oct 21
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
467
-0.22%
|
$56,040
$120.76 P/Share
|
|
Oct 21
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+0.31%
|
-
|
|
Oct 21
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
143
+0.05%
|
-
|
|
Oct 20
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,522
+2.03%
|
-
|
|
Oct 20
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
3,386
+1.71%
|
-
|
|
Oct 20
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
856
+0.41%
|
-
|
|
Oct 20
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
190
+0.07%
|
-
|
|
Oct 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,523
-2.31%
|
$587,990
$130.4 P/Share
|
|
Oct 01
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-1.28%
|
$375,000
$125.58 P/Share
|
|
Oct 01
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.32%
|
$337,500
$125.69 P/Share
|